FOXD3 Is a Mutant B-RAF-Regulated Inhibitor of G1-S Progression in Melanoma Cells

被引:73
作者
Abel, Ethan V. [1 ]
Aplin, Andrew E. [1 ]
机构
[1] Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
关键词
BRAF MUTATIONS; PIGMENT-CELLS; LINEAGE; P53; ACTIVATION; EXPRESSION; PLURIPOTENCY; REQUIREMENT; P27(KIP1); KINASES;
D O I
10.1158/0008-5472.CAN-09-3139
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The forkhead box transcription factor FOXD3 is a stemness factor that prevents the production of melanocyte progenitors from the developing neural crest; however, its role in human cancers is not known. Transformation of melanocytes gives rise to melanoma. In two thirds of melanomas, the serine/threonine kinase B-RAF is mutated to a constitutively active form. Here, we show that FOXD3 levels are upregulated following attenuation of B-RAF and mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK) signaling in mutant B-RAF harboring human melanoma cells. This effect was selective because FOXD3 was not upregulated following MEK inhibition in wild-type B-RAF melanoma cells and mutant B-RAF thyroid carcinoma cells. Ectopic FOXD3 expression potently inhibited melanoma cell growth without altering mutant B-RAF activation of ERK1/2. Inhibition of cell growth was due to a potent G(1) cell cycle arrest and was associated with p53-dependent upregulation of p21(Cip1). FOXD3-induced cell cycle arrest was prevented by p53 depletion and, to a lesser extent, p21(Cip1) depletion. These studies show that FOXD3 is suppressed by B-RAF, uncover a novel role and mechanism for FOXD3 as a negative cell cycle regulator, and have implications for the repression of melanocytic lineage cells. Cancer Res; 70(7); 2891-900. (C) 2010 AACR.
引用
收藏
页码:2891 / 2900
页数:10
相关论文
共 45 条
[1]   Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells [J].
Bhatt, K. V. ;
Hu, R. ;
Spofford, L. S. ;
Aplin, A. E. .
ONCOGENE, 2007, 26 (07) :1056-1066
[2]   Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling [J].
Bhatt, KV ;
Spofford, LS ;
Aram, G ;
McMullen, M ;
Pumiglia, K ;
Aplin, AE .
ONCOGENE, 2005, 24 (21) :3459-3471
[3]   Mutant B-RAF mediates resistance to anoikis via Bad and Bim [J].
Boisvert-Adamo, K. ;
Aplin, A. E. .
ONCOGENE, 2008, 27 (23) :3301-3312
[4]   B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis [J].
Boisvert-Adamo, K. ;
Aplin, A. E. .
ONCOGENE, 2006, 25 (35) :4848-4856
[5]   The p21Cip1 and p27Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts [J].
Cheng, MG ;
Olivier, P ;
Diehl, JA ;
Fero, M ;
Roussel, MF ;
Roberts, JM ;
Sherr, CJ .
EMBO JOURNAL, 1999, 18 (06) :1571-1583
[6]   Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells [J].
Conner, SR ;
Scott, G ;
Aplin, AE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (36) :34548-34554
[7]   AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases:: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models [J].
Davies, Barry R. ;
Logie, Armelle ;
McKay, Jennifer S. ;
Martin, Paul ;
Steele, Samantha ;
Jenkins, Richard ;
Cockerill, Mark ;
Cartlidge, Sue ;
Smith, Paul D. .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (08) :2209-2219
[8]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[9]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825
[10]   Identification of a novel inhibitor of mitogen-activated protein kinase kinase [J].
Favata, MF ;
Horiuchi, KY ;
Manos, EJ ;
Daulerio, AJ ;
Stradley, DA ;
Feeser, WS ;
Van Dyk, DE ;
Pitts, WJ ;
Earl, RA ;
Hobbs, F ;
Copeland, RA ;
Magolda, RL ;
Scherle, PA ;
Trzaskos, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (29) :18623-18632